Gilead Sciences Announces Third Quarter 2012 Financial Results

  Gilead Sciences Announces Third Quarter 2012 Financial Results

 - Product Sales of $2.36 Billion, Up 14 Percent over Third Quarter of 2011 -

 - Antiviral Product Sales of $2.04 Billion, Up 13 Percent over Third Quarter
                                  of 2011 -

Business Wire

FOSTER CITY, Calif. -- October 23, 2012

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations
for the quarter ended September30, 2012. Total revenues for the third quarter
of 2012 increased 14 percent to $2.43 billion, from $2.12 billion for the
third quarter of 2011. Net income for the third quarter of 2012 was $675.5
million, or $0.85 per diluted share compared to $741.1 million, or $0.95 per
diluted share for the third quarter of 2011. Non-GAAP net income for the third
quarter of 2012, which excludes acquisition-related, restructuring and
stock-based compensation expenses, was $788.9 million, or $1.00 per diluted
share compared to $795.2 million, or $1.02 per diluted share for the third
quarter of 2011.

Product Sales

Product sales increased 14 percent to $2.36 billion for the third quarter of
2012 compared to $2.07 billion for the third quarter of 2011. This increase in
product sales was due primarily to Gilead's antiviral franchise, resulting
from increased sales of Complera^®/Eviplera^® (emtricitabine 200
mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg), Atripla^®
(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
and Truvada^® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) as
well as the launch of Stribild^TM (elvitegravir 150 mg/cobicistat 150
mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg).

Antiviral Franchise

Antiviral product sales increased 13 percent to $2.04 billion for the third
quarter of 2012, up from $1.79 billion for the third quarter of 2011,
reflecting sales growth of 19 percent in the U.S. and 5 percent in Europe.

  *Atripla
    Sales of Atripla increased 9 percent to $865.4 million for the third
    quarter of 2012, up from $794.7 million for the third quarter of 2011,
    reflecting sales growth of 8 percent in the U.S. and 6 percent in Europe.

  *Truvada
    Sales of Truvada increased 8 percent to $804.2 million for the third
    quarter of 2012, up from $744.7 million for the third quarter of 2011,
    reflecting sales growth of 16 percent in the U.S. and 3 percent in Europe.

  *Viread
    Sales of Viread^® (tenofovir disoproxil fumarate) increased 11 percent to
    $214.9 million for the third quarter of 2012, up from $192.9 million for
    the third quarter of 2011, reflecting sales growth of 13 percent in the
    U.S. partially offset by a decrease of 1 percent in Europe.

  *Complera/Eviplera
    Sales of Complera/Eviplera grew more than fivefold to $99.3 million for
    the third quarter of 2012 compared to $19.0 million for the third quarter
    of 2011. Complera was approved in the U.S. in August 2011, and Eviplera
    was approved in the European Union in November 2011.

  *Stribild
    Sales of our newest product, Stribild, which was launched in the U.S. in
    August 2012, were $17.5 million for the third quarter of 2012.

Cardiopulmonary Franchise

Cardiopulmonary product sales increased 24 percent to $200.1 million for the
third quarter of 2012, up from $160.9 million for the third quarter of 2011.

  *Letairis
    Sales of Letairis^® (ambrisentan) increased 33 percent to $105.1 million
    for the third quarter of 2012, up from $79.0 million for the third quarter
    of 2011.

  *Ranexa
    Sales of Ranexa^®(ranolazine) increased 16 percent to $95.1 million for
    the third quarter of 2012, up from $82.0 million for the third quarter of
    2011.

Other Products

Sales of other products were $122.0 million for the third quarter of 2012
compared to $110.3 million for the third quarter of 2011 and included
AmBisome^® (amphotericin B) liposome for injection and Cayston^® (aztreonam
for inhalation solution).

Royalty, Contract and Other Revenues

Royalty, contract and other revenues were $68.6 million for the third quarter
of 2012, up 23 percent from $55.8 million for the third quarter of 2011, due
to an increase in royalty revenues, which included higher royalties from
GlaxoSmithKline Inc. for Volibris^® and Japan Tobacco for Truvada.

Research and Development Expenses

Research and development (R&D) expenses for the third quarter of 2012 were
$465.8 million compared to $290.1 million for the third quarter of 2011.
Non-GAAP R&D expenses for the third quarter of 2012, which exclude
acquisition-related, restructuring and stock-based compensation expenses, were
$383.6 million compared to $269.3 million for the third quarter of 2011 due
primarily to the continued advancement of Gilead's product pipeline,
particularly in liver disease and oncology.

Selling, General and Administrative Expenses

Selling, general and administrative (SG&A) expenses for the third quarter of
2012 were $319.6 million compared to $295.9 million for the third quarter of
2011. Non-GAAP SG&A expenses for the third quarter of 2012, which exclude
acquisition-related, restructuring and stock-based compensation expenses, were
$287.2 million compared to $265.1 million for the third quarter of 2011 due
primarily to increased expenses to support the ongoing growth of Gilead's
business and an increase in the U.S. pharmaceutical excise tax, partially
offset by lower bad debt expense.

Interest Expense and Other Income (Expense), Net

Interest expense for the third quarter of 2012 was $89.3 million compared to
$43.1 million for the third quarter of 2011. The increase was due primarily to
the additional debt issued in connection with the acquisition of Pharmasset
Inc. (Pharmasset). Other income (expense), net for the third quarter of 2012
was a net expense of $3.5 million compared to net income of $14.4 million in
the third quarter of 2011. The change was due primarily to decreased interest
income resulting from lower cash, cash equivalents and marketable securities
and lower yields.

Net Foreign Currency Exchange Impact

The net foreign currency exchange impact on third quarter 2012 product sales
and pre-tax earnings was an unfavorable $20.5 million and $7.2 million,
respectively, compared to the third quarter of 2011.

Cash, Cash Equivalents and Marketable Securities

As of September30, 2012, Gilead had $2.65 billion of cash, cash equivalents
and marketable securities compared to $9.96 billion as of December 31, 2011.
The decrease was due to the acquisition of Pharmasset in the first quarter of
2012. Gilead generated $2.49 billion of operating cash flow during the first
nine months of 2012 including $745.4 million generated in the third quarter of
2012. The operating cash flow for the first nine months of 2012 includes the
collection of $460 million of accounts receivable in Spain.

Corporate Highlights

In August, Gilead together with Mylan Laboratories, Ranbaxy Laboratories
Limited and Strides Arcolab, announced a collaboration agreement to promote
access to high-quality, low-cost generic versions of Gilead's HIV medicine
emtricitabine in developing countries - including single tablet regimens
containing emtricitabine, and fixed-dose combinations of emtricitabine
co-formulated with other Gilead HIV medicines.

Product and Pipeline Update

Antiviral Franchise

In July, Gilead announced:

  *The U.S. Food and Drug Administration (FDA) approved once-daily oral
    Truvada, in combination with safer sex practices, to reduce the risk of
    sexually acquired HIV-1 infection in adults at high risk for acquiring
    HIV. Truvada is the first drug to be approved for HIV prevention in
    uninfected adults, a strategy called pre-exposure prophylaxis (PrEP).
  *24-week data from a Phase 3 clinical trial, SPIRIT  (Switching boosted PI
    to Rilpivirine In Combination with Truvada as a Single Tablet Regimen),
    which evaluated virologically suppressed treatment-experienced HIV
    patients switching from a multi-pill regimen containing a
    ritonavir-boosted protease inhibitor to the once-daily single tablet
    regimen Complera. The study met its 24-week primary endpoint, which found
    that switching to Complera was non-inferior to remaining on a
    ritonavir-boosted protease inhibitor regimen. The findings were presented
    in an oral session at the 19th International AIDS Conference in
    Washington, D.C.
  *Two-year Phase 3 clinical trial results showing that the integrase
    inhibitor elvitegravir dosed once daily is non-inferior to raltegravir
    dosed twice daily among treatment-experienced HIV patients. The findings
    were presented in an oral session at the 19th International AIDS
    Conference in Washington, D.C.
  *Full clinical trial results from a pivotal Phase 3 study evaluating
    cobicistat, a pharmacoenhancing or “boosting” agent for HIV therapy,
    compared to ritonavir, currently the only approved agent used to boost
    certain antiretroviral treatment regimens. The study found that an HIV
    regimen containing a cobicistat-boosted protease inhibitor was
    non-inferior to a regimen containing a ritonavir-boosted protease
    inhibitor at 48 weeks of therapy. The findings were presented in an oral
    session at the 19th International AIDS Conference in Washington, D.C.

In August, the FDA approved Stribild, a complete once-daily single tablet
regimen for the treatment of HIV-1 infection in treatment-naïve adults.
Stribild, previously referred to as “Quad” prior to FDA approval, combines
four compounds in one daily tablet: elvitegravir, cobicistat, emtricitabine
and tenofovir disoproxil fumarate.

Conference Call

At 4:15 p.m. Eastern Time today, Gilead's management will host a conference
call and a simultaneous webcast to discuss results from its third quarter
2012, provide an update on Gilead's full year 2012 guidance, as well as
provide a general business update, including an update on pipeline
advancements. To access the webcast live via the internet, please connect to
the company's website at www.gilead.com 15 minutes prior to the conference
call to ensure adequate time for any software download that may be needed to
hear the webcast. Alternatively, please call 1-800-659-1966 (U.S.) or
1-617-614-2711 (international) and dial the participant passcode 31853534 to
access the call.

A replay of the webcast will be archived on the company's website for one
year, and a phone replay will be available approximately two hours following
the call through October 26, 2012. To access the phone replay, please call
1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the
participant passcode 84574172.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need. The
company's mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia Pacific.

Non-GAAP Financial Information

Gilead has presented certain financial information in accordance with U.S.
GAAP (GAAP) and also on a non-GAAP basis for the third quarter of 2012 and
2011. Management believes this non-GAAP information is useful for investors,
taken in conjunction with Gilead's GAAP financial statements, because
management uses such information internally for its operating, budgeting and
financial planning purposes. Non-GAAP information is not prepared under a
comprehensive set of accounting rules and should only be used to supplement an
understanding of Gilead's operating results as reported under U.S. GAAP. A
reconciliation between GAAP and non-GAAP financial information is provided in
the table on page 7.

Forward-looking Statements

Statements included in this press release that are not historical in nature
are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Gilead cautions readers that forward-looking
statements are subject to certain risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties include:
Gilead's ability to achieve its anticipated full year 2012 financial results;
Gilead's ability to sustain growth in revenues for its antiviral,
cardiopulmonary and respiratory franchises; the availability of funding for
state AIDS Drug Assistance Programs (ADAPs) and their ability to purchase at
levels to support the number of patients that rely on ADAPs; continued
fluctuations in ADAP purchases driven by federal and state grant cycles which
may not mirror patient demand and may cause fluctuations in Gilead's earnings;
the possibility of unfavorable results from additional arms of the ATOMIC,
ELECTRON and QUANTUM studies and subsequent clinical trials involving GS-7977
and ribavirin and GS-7977 plus pegylated interferon and ribavirin; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in
Gilead's earnings; Gilead's ability to submit new drug applications for new
product candidates in the timelines currently anticipated, including GS-7977
for the treatment of hepatitis C (HCV); Gilead's ability to receive regulatory
approvals in a timely manner or at all, for new and current products,
including cobicistat or elvitegravir; Gilead's ability to successfully
commercialize its products, including Complera/Eviplera and Stribild; Gilead's
ability to successfully develop its respiratory, cardiopulmonary and oncology
franchises; safety and efficacy data from clinical studies may not warrant
further development of Gilead's product candidates, including GS-7977; the
potential for additional austerity measures in European countries that may
increase the amount of discount required on Gilead's products; fluctuations in
the foreign exchange rate of the U.S. dollar that may cause an unfavorable
foreign currency exchange impact on Gilead's future revenues and pre-tax
earnings; Gilead's ability to advance Pharmasset's product pipeline or develop
an all-oral antiviral regimen for HCV; and other risks identified from time to
time in Gilead's reports filed with the U.S. Securities and Exchange
Commission. In addition, Gilead makes estimates and judgments that affect the
reported amounts of assets, liabilities, revenues and expenses and related
disclosures. Gilead bases its estimates on historical experience and on
various other market-specific and other relevant assumptions that it believes
to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may differ
significantly from these estimates. You are urged to consider statements that
include the words may, will, would, could, should, might, believes, estimates,
projects, potential, expects, plans, anticipates, intends, continues,
forecast, designed, goal, or the negative of those words or other comparable
words to be uncertain and forward-looking. Gilead directs readers to its
Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and other
subsequent disclosure documents filed with the Securities and Exchange
Commission and press releases. Gilead claims the protection of the Safe Harbor
contained in the Private Securities Litigation Reform Act of 1995 for
forward-looking statements. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.

 We own or have rights to various trademarks, copyrights and trade names used
    in our business, including the following: GILEAD^®, GILEAD SCIENCES^®,
TRUVADA^®, VIREAD^®, HEPSERA^®, AMBISOME^®, EMTRIVA^®, COMPLERA^®, EVIPLERA^®,
   STRIBILD^TM, VISTIDE^®, LETAIRIS^®, VOLIBRIS^®, RANEXA^®, CAYSTON^® and
  RAPISCAN^®. ATRIPLA^® is a registered trademark belonging to Bristol-Myers
                        Squibb& Gilead Sciences, LLC.

     LEXISCAN^® is a registered trademark belonging to Astellas U.S. LLC.

   MACUGEN^® is a registered trademark belonging to Valeant Pharmaceuticals
                             International, Inc.

 SUSTIVA^® is a registered trademark of Bristol-Myers Squibb Pharma Company.

   TAMIFLU^® is a registered trademark belonging to Hoffmann-La Roche Inc.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or
call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

                                              
GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in thousands, except per share amounts)
                                                
                 2012           2011            2012           2011
Revenues:
Product sales    $ 2,357,978     $ 2,065,859     $ 6,887,560     $ 5,969,025
Royalty,
contract and     68,619         55,801         226,672        215,982     
other revenues
Total revenues   2,426,597      2,121,660      7,114,232      6,185,007   
Costs and
expenses:
Cost of goods    597,269         531,989         1,795,545       1,539,963
sold
Research and     465,831         290,066         1,320,286       826,915
development
Selling,
general and      319,583        295,927        1,095,209      895,764     
administrative
Total costs      1,382,683      1,117,982      4,211,040      3,262,642   
and expenses
Income from      1,043,914       1,003,678       2,903,192       2,922,365
operations
Interest         (89,322     )   (43,097     )   (275,010    )   (130,420    )
expense
Other income     (3,505      )   14,406         (38,665     )   40,216      
(expense), net
Income before
provision for    951,087         974,987         2,589,517       2,832,161
income taxes
Provision for    280,052        237,449        774,877        704,861     
income taxes
Net income       671,035         737,538         1,814,640       2,127,300
Net loss
attributable
to               4,470          3,586          14,385         11,192      
noncontrolling
interest
Net income
attributable     $ 675,505      $ 741,124      $ 1,829,025    $ 2,138,492 
to Gilead
Net income per
share
attributable
to Gilead        $ 0.89         $ 0.97         $ 2.42         $ 2.72      
common
stockholders -
basic
Net income per
share
attributable
to Gilead        $ 0.85         $ 0.95         $ 2.33         $ 2.66      
common
stockholders -
diluted
Shares used in
per share        757,385        767,033        757,032        787,272     
calculation -
basic
Shares used in
per share        792,304        781,312        783,824        802,762     
calculation -
diluted
                                                                             

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

(in thousands, except percentages and per share amounts)
                                                
                       2012         2011          2012           2011
Cost of goods sold
reconciliation:
GAAP cost of goods     $ 597,269     $ 531,989     $ 1,795,545     $ 1,539,963
sold
Stock-based
compensation           (1,864    )   (2,234    )   (6,084      )   (7,765      )
expenses
Acquisition
related-amortization   (15,837   )   (17,407   )   (47,509     )   (52,222     )
of purchased
intangibles
Non-GAAP cost of       $ 579,568    $ 512,348    $ 1,741,952    $ 1,479,976 
goods sold
                                                                   
Product gross margin
reconciliation:
GAAP product gross     74.7      %   74.3      %   74.0        %   74.3        %
margin
Stock-based
compensation           0.1       %   0.1       %   0.1         %   0.1         %
expenses
Acquisition
related-amortization   0.7       %   0.8       %   0.7         %   0.9         %
of purchased
intangibles
Non-GAAP product       75.5      %   75.3      %   74.8        %   75.3        %
gross margin^(1)
                                                                   
Research and
development expenses
reconciliation:
GAAP research and      $ 465,831     $ 290,066     $ 1,320,286     $ 826,915
development expenses
Stock-based
compensation           (23,236   )   (18,389   )   (162,214    )   (54,529     )
expenses
Restructuring          (232      )   (806      )   (7,322      )   (1,360      )
expenses
Acquisition
related-transaction    —             —             (345        )   (446        )
costs
Acquisition
related-contingent     (58,810   )   (1,616    )   (64,116     )   (1,198      )
consideration
remeasurement
Non-GAAP research
and development        $ 383,553    $ 269,255    $ 1,086,289    $ 769,382   
expenses
                                                                   
Selling, general and
administrative
expenses
reconciliation:
GAAP selling,
general and            $ 319,583     $ 295,927     $ 1,095,209     $ 895,764
administrative
expenses
Stock-based
compensation           (29,364   )   (25,897   )   (177,237    )   (83,821     )
expenses
Restructuring          (2,792    )   (4,388    )   (13,199     )   (6,054      )
expenses
Acquisition
related-transaction    (222      )   (535      )   (11,096     )   (1,278      )
costs
Non-GAAP selling,
general and            $ 287,205    $ 265,107    $ 893,677      $ 804,611   
administrative
expenses
                                                                   
Operating margin
reconciliation:
GAAP operating         43.0      %   47.3      %   40.8        %   47.2        %
margin
Stock-based
compensation           2.2       %   2.2       %   4.9         %   2.4         %
expenses
Restructuring          0.1       %   0.2       %   0.3         %   0.1         %
expenses
Acquisition
related-transaction    0.0       %   0.0       %   0.2         %   0.0         %
costs
Acquisition
related-amortization   0.7       %   0.8       %   0.7         %   0.8         %
of purchased
intangibles
Acquisition
related-contingent     2.4       %   0.1       %   0.9         %   0.0         %
consideration
remeasurement
Non-GAAP operating     48.5      %   50.7      %   47.7        %   50.6        %
margin^(1)
                                                                   
Interest expense
reconciliation:
GAAP interest          $ (89,322 )   $ (43,097 )   $ (275,010  )   $ (130,420  )
expense
Acquisition
related-transaction    —            —            7,333          —           
costs
Non-GAAP interest      $ (89,322 )   $ (43,097 )   $ (267,677  )   $ (130,420  )
expense
                                                                   
Net income
attributable to
Gilead
reconciliation:
GAAP net income
attributable to        $ 675,505     $ 741,124     $ 1,829,025     $ 2,138,492
Gilead, net of tax
Stock-based
compensation           39,442        35,221        304,282         109,750
expenses
Restructuring          2,165         3,908         14,937          5,569
expenses
Acquisition
related-transaction    123           535           13,665          1,724
costs
Acquisition
related-amortization   11,462        13,172        34,581          39,225
of purchased
intangibles
Acquisition
related-contingent     60,243       1,213        64,116         900         
consideration
remeasurement
Non-GAAP net income
attributable to        $ 788,940    $ 795,173    $ 2,260,606    $ 2,295,660 
Gilead, net of tax
                                                                   
Diluted earnings per
share
reconciliation:
GAAP diluted           $ 0.85        $ 0.95        $ 2.33          $ 2.66
earnings per share
Stock-based
compensation           0.05          0.05          0.39            0.14
expenses
Restructuring          0.00          0.01          0.02            0.01
expenses
Acquisition
related-transaction    0.00          0.00          0.02            0.00
costs
Acquisition
related-amortization   0.01          0.02          0.04            0.05
of purchased
intangibles
Acquisition
related-contingent     0.08         0.00         0.08           0.00        
consideration
remeasurement
Non-GAAP diluted
earnings per           $ 1.00       $ 1.02       $ 2.89         $ 2.87      
share^(1)
                                                                   
Shares used in per
share calculation
(diluted)
reconciliation:
GAAP shares used in
per share              792,304       781,312       783,824         802,762
calculation
(diluted)
Share impact of
current stock-based    (1,310    )   (2,096    )   (1,427      )   (2,007      )
compensation rules
Non-GAAP shares used
in per share           790,994      779,216      782,397        800,755     
calculation
(diluted)
                                                                   
Non-GAAP adjustment
summary:
Cost of goods sold     $ 17,701      $ 19,641      $ 53,593        $ 59,987
adjustments
Research and
development expenses   82,278        20,811        233,997         57,533
adjustments
Selling, general and
administrative         32,378        30,820        201,532         91,153
expenses adjustments
Interest expense       —            —            7,333          —           
adjustments
Total non-GAAP
adjustments before     132,357       71,272        496,455         208,673
tax
Income tax effect      (18,922   )   (17,223   )   (64,874     )   (51,505     )
Total non-GAAP
adjustments after      $ 113,435    $ 54,049     $ 431,581      $ 157,168   
tax
                                                                   
Note:
(1) Amounts may not sum due to rounding


GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)
                                                               
                                                 September 30,    December 31,
                                                 2012             2011
                                                 (unaudited)      (Note 1)
Cash, cash equivalents and marketable            $ 2,651,088      $ 9,963,972
securities
Accounts receivable, net                         1,766,091        1,951,167
Inventories                                      1,617,369        1,389,983
Property, plant and equipment, net               856,184          774,406
Intangible assets, net                           11,735,354       1,062,864
Goodwill                                         1,078,919        1,004,102
Other assets                                     1,258,824       1,156,640
Total assets                                     $ 20,963,829    $ 17,303,134
                                                                  
Current liabilities                              $ 4,802,148      $ 2,514,790
Long-term liabilities                            7,411,519        7,920,995
Stockholders’ equity (Note 2)                    8,750,162       6,867,349
Total liabilities and stockholders’ equity       $ 20,963,829    $ 17,303,134

Notes:
(1) Derived from the audited consolidated financial statements as of December
31, 2011.
(2) As of September 30, 2012, there were 757,933 shares of common stock issued
and outstanding.


GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

(in thousands)
                                                
                   2012           2011            2012           2011
Antiviral
products:
Atripla – U.S.     $ 539,797       $ 501,576       $ 1,672,676     $ 1,474,580
Atripla – Europe   270,273         254,957         821,094         775,167
Atripla – Other    55,308         38,166         163,227        111,456
International
                   865,378        794,699        2,656,997      2,361,203
                                                                   
Truvada – U.S.     414,452         357,660         1,180,791       1,011,837
Truvada – Europe   329,936         319,149         980,626         940,312
Truvada – Other    59,802         67,918         186,969        176,990
International
                   804,190        744,727        2,348,386      2,129,139
                                                                   
Viread – U.S.      98,969          87,712          282,737         240,420
Viread – Europe    81,962          82,927          250,955         245,062
Viread – Other     33,978         22,248         88,324         61,517
International
                   214,909        192,887        622,016        546,999
                                                                   
Complera /         82,099          19,044          195,742         19,044
Eviplera – U.S.
Complera /
Eviplera –         14,306          —               24,771          —
Europe
Complera /
Eviplera – Other   2,892          —              3,873          —
International
                   99,297         19,044         224,386        19,044
                                                                   
Stribild – U.S.    17,511         —              17,511         —
                                                                   
Hepsera – U.S.     12,615          14,170          33,596          42,809
Hepsera – Europe   11,999          18,223          41,384          60,293
Hepsera – Other    2,705          3,238          7,827          9,281
International
                   27,319         35,631         82,807         112,383
                                                                   
Emtriva – U.S.     4,717           4,666           13,580          12,482
Emtriva – Europe   1,617           1,772           5,169           5,162
Emtriva – Other    895            1,229          3,070          3,331
International
                   7,229          7,667          21,819         20,975
                                                                   
Total Antiviral    1,170,160       984,828         3,396,633       2,801,172
products – U.S.
Total Antiviral
products –         710,093         677,028         2,123,999       2,025,996
Europe
Total Antiviral
products – Other   155,580        132,799        453,290        362,575
International
                   2,035,833      1,794,655      5,973,922      5,189,743
                                                                   
Letairis           105,054         78,954          293,976         214,765
Ranexa             95,066          81,983          273,822         236,353
AmBisome           87,448          82,241          255,865         249,372
Other products     34,577         28,026         89,975         78,792
                   322,145        271,204        913,638        779,282
                                                                   
Total product      $ 2,357,978    $ 2,065,859    $ 6,887,560    $ 5,969,025
sales

Contact:

Gilead Sciences, Inc.
Investors
Robin Washington, 650-522-5688
Patrick O'Brien, 650-522-1936
or
Media
Amy Flood, 650-522-5643